Weight LossMar 15, 2026
Most people trying 16:8 fasting want to know one thing: what will actually be different in a month? The honest answer from clinical trials is that the changes are real but modest. Overweight adults who stick with a 16-hour fast and 8-hour eating window for about four weeks typically lose roughly 1 to 2 kilograms, with small but measurable improvements in insulin sensitivity and triglycerides. That's not nothing. But it's also not dramatic, and it depends heavily on whether you actually eat less overall.
The less comfortable truth is that the eating window itself isn't magic. Several large trials found that when people kept their total calorie intake the same, weight loss from 16:8 looked no different from ordinary dieting. The window works primarily because it makes it easier to eat less. If it doesn't do that for you, the scale probably won't move much.
DiabetesMar 15, 2026
A single patch the size of a postage stamp delivered semaglutide for an entire month in animal studies, mimicking four weekly injections from one 2×2 cm application. That is genuinely exciting. It is also, for now, entirely experimental. No GLP-1 patch is approved or commercially available for diabetes or obesity. Every current GLP-1 receptor agonist, including semaglutide, liraglutide, dulaglutide, and tirzepatide, reaches patients through injections or, in the case of oral semaglutide, a daily pill.
So if you have seen headlines about GLP-1 patches and wondered whether you should ask your doctor about one, the honest answer is: not yet. But the research pipeline is worth understanding, because it signals where treatment is headed.
Weight LossMar 15, 2026
Tirzepatide for weight loss isn't measured in "units" the way insulin is. It's prescribed in milligrams (mg), injected once a week, and follows a strict stepwise schedule. That milligram number turns out to be one of the strongest predictors of how much weight you'll lose: in the largest trial of non-diabetic adults with obesity, the difference between the lowest and highest maintenance doses was the difference between losing about 15% and nearly 21% of body weight over 72 weeks.
The dosing pattern across all major weight-loss trials is remarkably consistent. Start at 2.5 mg, climb slowly, settle into a maintenance dose of 5, 10, or 15 mg. Where you land on that ladder matters more than most people realize.
Sleep ApneaMar 15, 2026
For most people on positive airway pressure therapy, CPAP and BiPAP produce similar results on the outcomes that matter most: survival, avoiding intubation, and controlling sleep apnea. The research is consistent on this point across both acute hospital settings and long-term sleep disorder management. BiPAP isn't an upgrade from CPAP. It's a different tool, and the situations where it genuinely outperforms CPAP are more specific than many people realize.
The core difference is mechanical. CPAP (continuous positive airway pressure) pushes one steady pressure into your airway. BiPAP (bilevel positive airway pressure) delivers a higher pressure when you breathe in and a lower one when you breathe out. That second, lower pressure is what makes BiPAP feel easier to exhale against, and the higher inspiratory pressure can do extra work to help move air in and clear carbon dioxide.
MetforminMar 15, 2026
No clinical trial has ever compared morning versus evening metformin dosing for weight loss. Not one. The question sounds reasonable, but the research simply hasn't found that clock time matters. What does matter: your total daily dose, whether you can tolerate it, and how long you stick with it.
Metformin produces real but modest weight loss in people with overweight or obesity, roughly 0.5 BMI units, or about 2 to 3 percent of body weight, over three months or more at doses ranging from 500 to 2,550 mg per day. That's meaningful, but it's not dramatic, and trying to optimize the hour you swallow the pill won't change that math.
Metabolic HealthMar 15, 2026
TMG (trimethylglycine, also called betaine) does something frustrating. According to meta-analysis data, it reliably lowers homocysteine by about 1.3 µmol/L, a marker linked to cardiovascular risk. But it simultaneously raises total and LDL cholesterol, particularly at doses of 4 grams per day or higher. That's not a minor footnote. It's the central tension in the TMG story, and it should shape how you think about supplementing.
Marketed for everything from heart health to gym performance to liver support, TMG is a naturally occurring compound involved in methylation, osmotic balance, and metabolism. The animal research looks impressive. The human research looks far more modest, and sometimes contradictory. Here's where things actually stand.
Weight ManagementMar 14, 2026
Spironolactone does not cause clinically meaningful weight gain. Across every population studied, from heart failure patients to women with PCOS to obese postmenopausal women, the pattern is consistent: weight either stays the same or drops slightly. In one large cardiovascular trial with over 1,700 patients, spironolactone actually cut the odds of gaining significant weight nearly in half during the first year.
That's a notably clean signal for a medication many people worry about. If you've been prescribed spironolactone and Googled the side effects list, you may have seen "weight gain" mentioned. The clinical evidence tells a different story.
MedicationsMar 14, 2026
Fluoxetine, sold as Prozac, is one of the most widely prescribed antidepressants on the planet, and one of the most common fears people have about starting it is gaining weight. But when you look at the actual human trial data, the picture flips. Meta-analyses of randomized trials in overweight and obese adults show fluoxetine produces modest weight loss of roughly 1 to 3 kg compared to placebo, particularly at doses of 60 mg/day or higher over 12 weeks or less. A large systematic review of psychotropic medications found fluoxetine associated with an average 1.3 kg loss.
That's not a typo. The drug most people worry will make them heavier is, if anything, slightly more likely to make them lighter.
Pain ManagementMar 13, 2026
Most episodes of lumbago, the clinical term for low back pain, improve over weeks regardless of what treatment you pursue. That's not a comforting platitude. It's a consistent finding across international clinical guidelines: the typical course of acute and subacute low back pain is resolution over a matter of weeks. The real challenge isn't finding some magic fix. It's resisting the urge to do too much.
Low back pain is the leading cause of years lived with disability worldwide, affecting roughly 619 million people as of 2020, with projections reaching about 843 million by 2050. Despite that staggering burden, the vast majority of cases are "non-specific," meaning no single clear structural cause can be pinpointed. And only a minority ever need surgery.
